Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.

[1]  R. Mayeux,et al.  Alcohol Intake and Risk of Dementia , 2004, Journal of the American Geriatrics Society.

[2]  K. Kosaka,et al.  Neuroleptic malignant syndrome induced by donepezil. , 2004, The international journal of neuropsychopharmacology.

[3]  Anabella Villalobos,et al.  Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. , 2004, European journal of pharmacology.

[4]  E. Peskind,et al.  The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. , 2004, Archives of neurology.

[5]  Manuela G. López,et al.  Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors , 2004, Neuropharmacology.

[6]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[7]  Roy W Jones,et al.  A multinational, randomised, 12‐week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease , 2004, International journal of geriatric psychiatry.

[8]  E. Giacobini.  Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease , 2003, Neurochemical Research.

[9]  D. Commenges,et al.  Intake of flavonoids and risk of dementia , 2000, European Journal of Epidemiology.

[10]  H. Brodaty,et al.  Efficacy and Safety of Donepezil in Patients with Alzheimer’s Disease , 2004, Drugs & aging.

[11]  Deborah Gustafson,et al.  Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. , 2004, Archives of neurology.

[12]  M. Rogawski,et al.  The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. , 2006, CNS drug reviews.

[13]  S. Ferris.  Evaluation of memantine for the treatment of Alzheimer’s disease , 2003, Expert opinion on pharmacotherapy.

[14]  Richard Schulz,et al.  End-of-life care and the effects of bereavement on family caregivers of persons with dementia. , 2003, The New England journal of medicine.

[15]  Xuejing Kang,et al.  Estradiol prevents amyloid-β peptide-induced cell death in a cholinergic cell line via modulation of a classical estrogen receptor , 2003, Neuroscience.

[16]  Michael A. Weber,et al.  Treating hypertension in the elderly: protagonist viewpoint. , 2003, American Journal of Geriatric Cardiology.

[17]  S. Wonnacott,et al.  The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. , 2003, Molecular pharmacology.

[18]  S. A. Areosa,et al.  Folic acid with or without vitamin B12 for cognition and dementia. , 2003, The Cochrane database of systematic reviews.

[19]  A. Członkowska,et al.  Influence of estrogens on neurodegenerative processes. , 2003, Medical science monitor : international medical journal of experimental and clinical research.

[20]  M. Sano,et al.  The effects of galantamine treatment on caregiver time in Alzheimer's disease , 2003, International journal of geriatric psychiatry.

[21]  M. Rapoport,et al.  Estrogen-induced changes in the microtubular system correlate with a decreased susceptibility of aging neurons to beta amyloid neurotoxicity , 2003, Molecular and Cellular Neuroscience.

[22]  G. Siegel,et al.  Intracerebroventricular passive immunization with anti‐Aβ antibody in Tg2576 , 2003, Journal of neuroscience research.

[23]  S. Brimijoin,et al.  Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex , 2003, Neurobiology of Aging.

[24]  Nathan Herrmann,et al.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[25]  S. Weggen,et al.  Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain* , 2003, Journal of Biological Chemistry.

[26]  D. Capuzzi,et al.  Hypercholesterolemia. The NCEP Adult Treatment Panel III Guidelines. , 2003, Geriatrics.

[27]  A. Akaike,et al.  Nicotinic Acetylcholine Receptor-Mediated Neuroprotection by Donepezil Against Glutamate Neurotoxicity in Rat Cortical Neurons , 2003, Journal of Pharmacology and Experimental Therapeutics.

[28]  D. Bennett,et al.  Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.

[29]  M. Etminan,et al.  Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies , 2003, BMJ : British Medical Journal.

[30]  M. Linton,et al.  A practical approach to risk assessment to prevent coronary artery disease and its complications. , 2003, The American journal of cardiology.

[31]  Paul F. Smith.  Therapeutic N-methyl-D-aspartate receptor antagonists: will reality meet expectation? , 2003, Current opinion in investigational drugs.

[32]  S. Brimijoin,et al.  Amyloid‐beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation , 2003, Journal of neurochemistry.

[33]  D. Geldmacher,et al.  Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease , 2003, Journal of the American Geriatrics Society.

[34]  D. Bennett,et al.  Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. , 2003, Archives of neurology.

[35]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[36]  A. Delacourte,et al.  Truncated beta‐amyloid peptide species in pre‐clinical Alzheimer's disease as new targets for the vaccination approach , 2003, Journal of neurochemistry.

[37]  Steven Potkin,et al.  Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. , 2003, Archives of neurology.

[38]  Martin Radina,et al.  Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors , 2003, Journal of Pharmacology and Experimental Therapeutics.

[39]  J. Manson,et al.  Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[40]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[41]  T. Iwatsubo,et al.  Sulindac Sulfide Is a Noncompetitive γ-Secretase Inhibitor That Preferentially Reduces Aβ42 Generation* , 2003, The Journal of Biological Chemistry.

[42]  Neil Chapman,et al.  Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. , 2003, Archives of internal medicine.

[43]  N. Tabet,et al.  Ibuprofen for Alzheimer's disease. , 2003, The Cochrane database of systematic reviews.

[44]  B. Strooper,et al.  Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex , 2003, Neuron.

[45]  Rachelle Doody,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[46]  J. Mintzer,et al.  The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure , 2003, International journal of geriatric psychiatry.

[47]  G. Vega,et al.  Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. , 2003, Archives of neurology.

[48]  S. Shoji,et al.  Neuroleptic malignant-like syndrome due to donepezil and maprotiline , 2003, Neurology.

[49]  S. Asthana,et al.  17β-Estradiol Reduces Plasma Aβ40 for HRT-Naïve Postmenopausal Women With Alzheimer Disease: A Preliminary Study , 2003 .

[50]  S. Brangman.  Long-term cholinesterase inhibitor therapy for Alzheimer's disease: Implications for long-term care , 2003, American journal of Alzheimer's disease and other dementias.

[51]  Andrea Russo,et al.  Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. , 2003, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[52]  S. Hartmann,et al.  Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy , 2003, International clinical psychopharmacology.

[53]  M. Michaelis.  Drugs Targeting Alzheimer's Disease: Some Things Old and Some Things New , 2003, Journal of Pharmacology and Experimental Therapeutics.

[54]  M. Wittekind,et al.  Comparative studies of active site-ligand interactions among various recombinant constructs of human beta-amyloid precursor protein cleaving enzyme. , 2003, Archives of biochemistry and biophysics.

[55]  A. Vagnucci,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Alzheimer's Disease and Angiogenesis , 2022 .

[56]  Qinying Zhao,et al.  Pharmacokinetic and Safety Assessments of Concurrent Administration of Risperidone and Donepezil , 2003, Journal of clinical pharmacology.

[57]  M. Michikawa.  The role of cholesterol in pathogenesis of Alzheimer's disease: dual metabolic interaction between amyloid beta-protein and cholesterol. , 2003, Molecular neurobiology.

[58]  R. Mayeux,et al.  Antioxidant vitamin intake and risk of Alzheimer disease. , 2003, Archives of neurology.

[59]  L. Schneider,et al.  Estrogen levels do not correlate with improvement in cognition. , 2003, Archives of neurology.

[60]  D. Murphy,et al.  The neuroprotective effects of estrogen on the aging brain , 2003, Experimental Gerontology.

[61]  E. Rimm,et al.  Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. , 2003, The New England journal of medicine.

[62]  Kristine Yaffe,et al.  Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. , 2003, JAMA.

[63]  A. Kurz,et al.  Galantamine Provides Sustained Benefits in Patients with ‘Advanced Moderate’ Alzheimer’s Disease for at Least 12 Months , 2003, Dementia and Geriatric Cognitive Disorders.

[64]  Luc Truyen,et al.  A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease , 2003, Drugs & aging.

[65]  C. Janus.  Vaccines for Alzheimer’s Disease , 2003, CNS drugs.

[66]  H. Allain,et al.  Clinically Significant Drug Interactions with Cholinesterase Inhibitors , 2003, CNS drugs.

[67]  S. Brimijoin,et al.  The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. , 2003, Drugs of today.

[68]  J. Rhodin,et al.  In vivo cerebrovascular actions of amyloid beta-peptides and the protective effect of conjugated estrogens. , 2003, Journal of Alzheimer's disease : JAD.

[69]  D. Butterfield,et al.  The Glutamatergic System and Alzheimer’s Disease , 2003, CNS drugs.

[70]  H. Geerts,et al.  Nicotinic cholinergic modulation: galantamine as a prototype. , 2006, CNS drug reviews.

[71]  Qiang Xu,et al.  Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins , 2002, Brain Research.

[72]  B. Winblad,et al.  An Economic Evaluation of Donepezil in Mild to Moderate Alzheimer’s Disease: Results of a 1-Year, Double-Blind, Randomized Trial , 2002, Dementia and Geriatric Cognitive Disorders.

[73]  A. Maelicke,et al.  Unconventional ligands and modulators of nicotinic receptors. , 2002, Journal of neurobiology.

[74]  W. Ma,et al.  Amyloid β peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures , 2002, Neuroscience.

[75]  M. Citron,et al.  Emerging Alzheimer’s disease therapies: inhibition of β-secretase , 2002, Neurobiology of Aging.

[76]  C. Patterson,et al.  Progress in Clinical Neurosciences: Treatment of Alzheimer’s Disease and Other Dementias - Review and Comparison of the Cholinesterase Inhibitors , 2002, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[77]  Karin Johnson,et al.  Vitamin nutrition in older adults. , 2002, Clinics in geriatric medicine.

[78]  K. Duff,et al.  Cholesterol in Alzheimer's Disease and Tauopathy , 2002, Annals of the New York Academy of Sciences.

[79]  Jan A Staessen,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002, Archives of internal medicine.

[80]  B. Winblad,et al.  Alcohol consumption and incidence of dementia in a community sample aged 75 years and older. , 2002, Journal of clinical epidemiology.

[81]  P. Zandi,et al.  Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study , 2002, Neurology.

[82]  John R. Fawcett,et al.  Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer’s brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants , 2002, Brain Research.

[83]  M. Farlow,et al.  GALANTAMINE PROVIDES BROAD BENEFITS IN PATIENTS WITH ‘ADVANCED MODERATE’ ALZHEIMER'S DISEASE (MMSE ≤12) FOR UP TO SIX MONTHS , 2002, International journal of clinical practice.

[84]  A. Nordberg,et al.  Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months , 2002, Neurology.

[85]  Arto Mannermaa,et al.  Apolipoprotein E 4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease , 2002, Annals of Internal Medicine.

[86]  Shih-ku Lin,et al.  Extrapyramidal side‐effect due to drug combination of risperidone and donepezil , 2002, Psychiatry and clinical neurosciences.

[87]  P. Wise.  Estrogens and neuroprotection , 2002, Trends in Endocrinology & Metabolism.

[88]  D. Beher,et al.  Gamma-secretase inhibition. , 2002, Biochemical Society transactions.

[89]  G. Siegel,et al.  Reversal of amyloid β toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid β antibody , 2002 .

[90]  R. Bullock,et al.  A MULTINATIONAL, RANDOMISED, 12‐WEEK, COMPARATIVE STUDY OF DONEPEZIL AND RIVASTIGMINE IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE , 2002, International journal of clinical practice.

[91]  Denis A. Evans,et al.  Vitamin E and cognitive decline in older persons. , 2002, Archives of neurology.

[92]  E. Giacobini,et al.  Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit , 2002, Journal of Neural Transmission.

[93]  A. Hofman,et al.  Dietary Intake of Antioxidants and Risk of Alzheimer Disease , 2002 .

[94]  D. Bennett,et al.  Dietary Intake of Antioxidant Nutrients and the Risk of Incident Alzheimer Disease in a Biracial Community Study , 2022 .

[95]  W. Perry,et al.  Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women: effect on lipids, coagulation factors, haematology and biochemistry. , 2002, Maturitas.

[96]  J. Poirier.  Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. , 2002, International journal of clinical practice. Supplement.

[97]  Claudio Soto,et al.  Reduction of amyloid load and cerebral damage in transgenic mouse model of Alzheimer's disease by treatment with a β‐sheet breaker peptide , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[98]  E. Peskind,et al.  Pharmacologic treatments of dementia. , 2002, The Medical clinics of North America.

[99]  P. Aisen.  Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. , 2002, Journal of pain and symptom management.

[100]  P. Zandi,et al.  Is pharmacological prevention of Alzheimer's a realistic goal? , 2002, Expert opinion on pharmacotherapy.

[101]  H. Fillit,et al.  The effect of donepezil therapy on health costs in a Medicare managed care plan. , 2002, Managed care interface.

[102]  Debomoy K Lahiri,et al.  Butyrylcholinesterase: An Important New Target in Alzheimer's Disease Therapy , 2002, International Psychogeriatrics.

[103]  Albert Hofman,et al.  Alcohol consumption and risk of dementia: the Rotterdam Study , 2002, The Lancet.

[104]  B. Vellas,et al.  Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with Donepezil , 2002, Current medical research and opinion.

[105]  Dirk Deleu,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.

[106]  B. Permanne,et al.  Are β-sheet breaker peptides dissolving the therapeutic problem of Alzheimer’s disease? , 2002 .

[107]  Sanjay Asthana,et al.  Estrogen and Alzheimer’s Disease , 2002, Drugs & aging.

[108]  B. Austen,et al.  Relation between cholesterol levels, statins and Alzheimer's disease in the human population. , 2002, The journal of nutrition, health & aging.

[109]  E. Giacobini.  Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. , 2002, Journal of neural transmission. Supplementum.

[110]  G. Small,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors , 2002, Clinical pharmacokinetics.

[111]  M. Reilly,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2001, The New England journal of medicine.

[112]  L. Wilkins.  To: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[113]  A. Hofman,et al.  Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. , 2001, The New England journal of medicine.

[114]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[115]  A. Ueki,et al.  [Malignant syndrome caused by a combination of bromperidol and donepezil hydrochloride in a patient with probable dementia with Lewy bodies]. , 2001, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[116]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[117]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[118]  A. Maelicke,et al.  Modulation of Nicotinic Receptor Activity in the Central Nervous System: A Novel Approach to the Treatment of Alzheimer Disease , 2001, Alzheimer disease and associated disorders.

[119]  S. Khosla,et al.  Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. , 2001, The Journal of clinical endocrinology and metabolism.

[120]  H. Soininen,et al.  Midlife vascular risk factors and late-life mild cognitive impairment , 2001, Neurology.

[121]  J Tuomilehto,et al.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.

[122]  A. Hofman,et al.  Antihypertensive drugs and incidence of dementia: the Rotterdam Study , 2001, Neurobiology of Aging.

[123]  J. Janowsky,et al.  Hormone replacement therapy and cognition: systematic review and meta-analysis. , 2001, JAMA.

[124]  R. Baserga.  Bird Song in His Heart , 2001, Science.

[125]  Alan C. Wilson,et al.  Correlates of Serum α- and γ-Tocopherol in the Women's Health Initiative , 2001 .

[126]  J. Staessen,et al.  Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. , 2001, Archives of internal medicine.

[127]  E G Stopa,et al.  Alzheimer's disease: a review concerning immune response and microischemia. , 2001, Medical hypotheses.

[128]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[129]  E. Shimizu,et al.  NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation. , 2000, Science.

[130]  L. Waite,et al.  Anti-inflammatory drugs protect against Alzheimer disease at low doses. , 2000, Archives of neurology.

[131]  R. Haley,et al.  Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? , 2000, Archives of neurology.

[132]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[133]  J. Staessen,et al.  Cerebral complications of hypertension , 2000, Journal of Human Hypertension.

[134]  S. Stahl.  The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. , 2000, The Journal of clinical psychiatry.

[135]  Hilkka Soininen,et al.  Relationship between apoE genotype and CSF β-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease , 2000, Neurobiology of Aging.

[136]  A. Maelicke.  Allosteric Modulation of Nicotinic Receptors as a Treatment Strategy for Alzheimer’s Disease , 2000, Dementia and Geriatric Cognitive Disorders.

[137]  G A Colditz,et al.  Moderate alcohol consumption and risk of coronary heart disease among women with type 2 diabetes mellitus. , 2000, Circulation.

[138]  J. Manson,et al.  Alcohol consumption and risk of coronary heart disease by diabetes status. , 2000, Circulation.

[139]  C. Barnes,et al.  Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors , 2000, Neuroscience.

[140]  J. Manson,et al.  Primary prevention of coronary heart disease in women through diet and lifestyle. , 2000, The New England journal of medicine.

[141]  M. Mega.  The cholinergic deficit in Alzheimer's disease: impact on cognition, behaviour and function. , 2000, The international journal of neuropsychopharmacology.

[142]  E. Peskind,et al.  Galantamine in AD , 2000, Neurology.

[143]  Agneta Nordberg,et al.  Neuronal nicotinic receptors in the human brain , 2000, Progress in Neurobiology.

[144]  R. Havlik,et al.  Association of vitamin E and C supplement use with cognitive function and dementia in elderly men , 2000, Neurology.

[145]  Anthony Gamst,et al.  Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .

[146]  A. Levey.  Molecules of the Brain , 2000, Hospital practice.

[147]  Y. Christen,et al.  Oxidative stress and Alzheimer disease. , 2000, The American journal of clinical nutrition.

[148]  R. Polinsky,et al.  Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. , 1999, Journal of clinical psychopharmacology.

[149]  D. Easton,et al.  Apolipoprotein E Genetic Variation and Alzheimer’s Disease , 1999, Dementia and Geriatric Cognitive Disorders.

[150]  E. Levin,et al.  Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer’s disease , 1999, Psychopharmacology.

[151]  B. Winblad,et al.  Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine) , 1999, International journal of geriatric psychiatry.

[152]  A. Nordberg.  PET studies and cholinergic therapy in Alzheimer's disease. , 1999, Revue neurologique.

[153]  F. Gejyo,et al.  Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's beta-amyloid fibril formation in vitro. , 1998, Biochemistry.

[154]  P. Sloane.  Advances in the treatment of Alzheimer's disease. , 1998, American family physician.

[155]  W. Burke,et al.  Extrapyramidal side effects in a patient treated with risperidone plus donepezil. , 1998, The American journal of psychiatry.

[156]  L. Beckett,et al.  Vitamin E and Vitamin C Supplement Use and Risk of Incident Alzheimer Disease , 1998, Alzheimer disease and associated disorders.

[157]  R Brookmeyer,et al.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.

[158]  R. Druckenbrod,et al.  Possible Association between Donepezil and Worsening Parkinson's Disease , 1998, The Annals of pharmacotherapy.

[159]  R. Polinsky,et al.  Dose‐dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease , 1998, Acta neurologica Scandinavica.

[160]  L. Amaducci,et al.  Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging , 1998, Neurology.

[161]  K. Yaffe,et al.  Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. , 1998, JAMA.

[162]  C. Behl.  Amyloid β-protein toxicity and oxidative stress in Alzheimer’s disease , 1997, Cell and Tissue Research.

[163]  M. Mullan,et al.  Superoxide free radical and intracellular calcium mediate Aβ 1–42 induced endothelial toxicity , 1997, Brain Research.

[164]  R. Brookmeyer,et al.  A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease , 1997, Neurology.

[165]  J. Mckenney,et al.  Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. , 1997, The American journal of cardiology.

[166]  C. Funck-Brentano,et al.  Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans , 1997, Clinical pharmacology and therapeutics.

[167]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[168]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[169]  A. Hofman,et al.  Histamine H2 Blocking Drugs and the Risk for Alzheimer’s Disease: The Rotterdam Study , 1997, Neurobiology of Aging.

[170]  E X Albuquerque,et al.  Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. , 1997, The Journal of pharmacology and experimental therapeutics.

[171]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[172]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[173]  M. Prince,et al.  Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults , 1996, BMJ.

[174]  A. Maelicke,et al.  New approach to drug therapy in Alzheimer's dementia Alfred Maelicke and Edson X. Albuquerque , 1996 .

[175]  E. Larson,et al.  Prevention of Alzheimer Disease: A Perspective Based on Successes in the Prevention of Other Chronic Diseases , 1996, Alzheimer disease and associated disorders.

[176]  B. K. Park,et al.  Clinical Pharmacokinetics of Tacrine , 1995, Clinical pharmacokinetics.

[177]  B. Långström,et al.  Kinetic Analysis of Regional (S)(-)11C‐Nicotine Binding in Normal and Alzheimer Brains In Vivo Assessment Using Positron Emission Tomography , 1995, Alzheimer disease and associated disorders.

[178]  D. Irving,et al.  Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology , 1995, Neuroscience.

[179]  C. Geula,et al.  Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia , 1994, Annals of neurology.

[180]  Gastone G. Celesia,et al.  A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .

[181]  P. Solomon,et al.  A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. , 1994, JAMA.

[182]  S. Lipton,et al.  Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.

[183]  J. Kastelein,et al.  Treatment of primary hypercholesterolaemia. Short‐term efficacy and safety of increasing doses of simvastatin and pravastatin: a double‐blind comparative study , 1993, Journal of internal medicine.

[184]  C. Hennekens,et al.  Light to Moderate Alcohol Consumption and Mortality in the Elderly , 1992, Journal of the American Geriatrics Society.

[185]  S. Gershon,et al.  Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[186]  T. Thomsen,et al.  Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. , 1990, Life sciences.

[187]  F. Forette,et al.  Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[188]  J. Penney,et al.  Glutamate transmission and toxicity in alzheimer's disease , 1988, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[189]  E. Perry,et al.  Intralaminar Neurochemical Distributions in Human Midtemporal Cortex: Comparison Between Alzheimer's Disease and the Normal , 1984, Journal of neurochemistry.

[190]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.